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Increasingevidencesuggeststhatthelossoffunctionalstemcellsmaybeimportantintheagingprocess.Our
experiments were originally aimed at testing the idea that, in the specific case of age-related osteoporosis,
declining function of osteogenic precursor cells might be at least partially responsible. To test this, aging
female mice were transplanted with mesenchymal stemcells from aged or young male donors. Wefind that
transplantation of young mesenchymal stem cells significantly slows the loss of bone density and,
surprisingly, prolongs the life span of old mice. These observations lend further support to the idea that
age-related diminution of stem cell number or function may play a critical role in age-related loss of bone
density in aging animals and may be one determinant of overall longevity.
O
steoporosis is a disease characterized by low bone mass and deteriorating bone structure leading to
increased bone fragility and risk of fractures
1,2. This disease, primarily affecting older population, has
placed atremendous burdenon the health care system
3,4.Althoughadvanced age is thebest predictor of
osteoporosis
1,3,thelinkbetween aging andosteoporosisis notfully understood. Ourinvestigations, involving the
simple strategy of introducing young bone marrow mesenchymal stem cells (BMSCs) into old recipients, were
intended to test the possibility that age-related loss of functional stem cells might be at least partially responsible
for this disorder.
Extensive evidence suggests that osteoporosis is caused by complex interactions between endogenous (genetic
andhormonal)andexogenous(nutritionalandphysicalactivity)factorsregulatingbonetissueremodeling
1,5.Itis
therefore thought that osteoporosis may be prevented by increased daily intake of calcium and vitamin D,
appropriate and persistent exercise, hormone replacement and many other alternative therapies
2,6. However,
none of these has been shown to be completely effective in preventing age-related osteoporosis.
It has recently been proposed that a decrease of osteogenic progenitor cells within the bone marrow with
advancingagemightberelatedtoosteoporosis
7,8.Inthisregard,arelativeincreaseintheproportionofosteoclasts
in aged bone may tilt the delicate balance between the bone-forming activity of osteoblasts and bone resorbing
activity of osteoclasts
7,8. A related proposal suggests that aging bone marrow cells may shift from pro-osteoblas-
togenesistopro-adipogenesisphenotypes,reflectedbyanaccumulationofbonemarrowfatwithaging
9.Inpartial
support of this possibility, stem cells isolated from older donors have been shown to have defective functions,
includingimpairedcapacityofproliferationanddifferentiationinvitro,comparedwiththoseisolatedfromyoung
individuals
10–12.
Despite of the latter observations, it remains uncertain whether aging of stem cells is responsible for the
pathogenesis of age-related osteoporosis. To test the possible impact of aging on stem cell function, we have
carriedoutaseriesofstudiestocomparethefunctionofBMSCsisolatedfromyoung(1–2monthsold)orold(20–
24 months old) mice. To test whether defective stem cells function might be responsible for the progression of
osteoporosis, old female mice were irradiated then transplanted with BMSCs from young or old males. The fate
and function of transplanted BMSCs and their effect on bone mineral density of elderly recipient mice were then
evaluated.
Results
Bonemarrowstemcellisolationandcharacterization.FemoralBMSCswereisolatedfrom1–2monthsoldand
20–24 months old male EGFP transgenic C57BL/6 mice and Balb/c mice. BMSCs from young and old EGFP
donorsshowedsimilarfibroblast-like spindle shapeandgreenfluorescence (Figure1A)followinginvitroculture
withsimilardoublingtimesof,80 hours.FlowcytometryanalysesshowedthatsecondpassagecellsfromBalb/c
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CD34, CD45 (Figure 1B). After culture in the presence of various
differentiation agents, BMSCs isolated from younger animals were
easily differentiated into osteogenic, adipogenic, neurogenic and
myogenic cell types. However, under similar culture conditions, we
found that BMSCs isolated from old animals had significantly less
capability to undergo osteogenic, adipogenic, neurogenic and
myogenic differentiation (Figure 1C). These results suggested that
BMSCslosetheabilitytodifferentiateintocertainlineagesduringthe
aging process.
Cellular senescence-related markers in BMSCs. Further studies
were carried out to determine whether BMSCs retrieved from
young or old mice might differ in terms of the presence of certain
cellular senescence markers, including DNA double-strand break
marker phosphorylated H2AX (c-H2AX), DNA damage
checkpoint response mediator 53BP1 (p53 gene binding protein 1).
These were analyzed in cultured BMSCs in vitro. Interestingly, we
found the DNA damage checkpoint response mediators 53BP1 and
c-H2AXweremuchhigherinBMSCsfromoldmicethanthosefrom
young mice (p50.014 and p51.71E24, respectively. Figure 2A–C).
BMSCs transplantation and migration in host mice. If a defect in
differentiation of aged BMSCs is responsible for osteoporosis, we
thought it likely that osteoporosis would be delayed with the
transplantation of BMSCs from young donors. To test this, we
irradiated 18–24 months old female Balb/C mice and then
transplanted them with 1 3 10
6 BMSCs isolated from either young
or old male EGFP C57BL/6 mice. To assess the effect of irradiation
on osteoblast activities, we evaluated alkaline phosphatase (AP)
activity in bone tissues. Interestingly, bone AP activities were
consistently lower in aged mice than in young mice (Figure 3A).
Immediately following irradiation, AP activities were substantially
reduced in both groups of mice indicating that radiation treatment
was effective in depleting resident osteoblast function in bones of
treated animals (Figure 3A).
Six months following transplantation, we analyzed femoral
bone from mice transplanted with either young or old BMSCs.
Surprisingly, we found significantly higher densities of GFP positive
BMSCs in the bone of mice transplanted with young BMSCs com-
pared to those given old BMSCs (p58.43E206; Figures 3B & 3C).
Furthermore, we found higher expression of osteocalcin (Figure 3B)
and higher numbers of alkaline phosphatase positive (AP1) cells
(Figure 3B) present in femurs of mice transplanted with young
BMSCs than those with old BMSCs (p53.83E25; Figure 3D).
These observations suggest that transplanted old BMSCs are rela-
tively unable to populate, replicate or differentiate into osteoblasts
within bones of aged recipients.
Figure 1 | Characterization of BMSCs. (A) BMSCs isolated from EGFP
transgenic C57BL/6 mice have typical fibroblast like morphology and
exhibit green fluorescence (320; bar5100mm). (B) Flow cytometry
analysis on BMSCs isolated from Balb/C mice shows the majority of cells
are CD1051, CD291, CD441, SCA-11, CD452, CD342. (C)
Differentiation capacity of BMSCs isolated from young (1–2 months old)
andold(20–24monthsold)Balb/Cmice.Theaverageratioofpositivecells
to total cells in three random 320 views was calculated as the
differentiation rate. N55 for each group.
Figure 2 | Expression of cellular senescence-related markers 53BP1 and
c-H2AX inBMSCsisolated fromyoungmice(1–2 months old,n53)and
agedfemaleBalb/Cmice(20–24monthsold,n53). (A)53BP1expression
(green) in BMSCs nuclei overlapping with DAPI staining (blue). (B)
c-H2AX expression (green) in BMSCs nuclei overlapping with DAPI
staining (blue). (C) Percentage of 53BP1 and c-H2AX positive cells in
BMSCs. *:p 50.014, **:p 51.71E-4.
www.nature.com/scientificreports
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Without further treatment, we noticed that most of the mice
transplanted with young BMSCs had a significantly longer life span
than other groups of mice (Figure 4A). The mean life span of control
mice was 765 days (Figure 4B). However, the mean life span for mice
that received young BMSCs transplants was 890 days (vs. control
group, p50.009). The increase of life span is probably unrelated to
radiation, since the mean life span of mice transplanted with old
BMSCs was 789 days (vs. young BMSCs transplants, p50.002)
(Figure 4B). In addition, there was no significant difference between
control animals and mice transplanted with old BMSCs (p50.846).
Overall, these results suggest that transplantation of BMSCs derived
fromyounganimalsextendslifespan.However,itisnotclearwhether
the prolonged lifespan may be associated with improved tissue
regeneration.
EffectsofBMSCsosteogenicactivitiesonbonemineraldensity.To
determine the effect of the osteogenic activities of transplanted
BMSCs on bone strength we measured the change of bone mineral
density (BMD) in the knee joint area of treated mice over time.
Untreated control Balb/C mice showed substantial bone density
increase with age from 1 month to 10 months (Figure 5A). The
bone density reached a plateau between 10 months to 12 months
of age. After 12 months, bone density started to decrease and the
decrease accelerated after 18 months (Figure 5A). Compared to
control mice, the mice transplanted with young BMSCs showed
substantially higher BMD distribution following transplantation at
18–24 months (and assessed at 20–32 months) (Figure 5B). On the
other hand, the BMD distribution of mice transplanted with old
BMSCs were lower than those of the control group or the young
BMSCs transplanted group (Figure 5C and D). By comparing the
mean bone mineral densities at different age ranges (Figure 5E), our
results clearly demonstrate that transplantation of young BMSCs
significantly delays the decrease of bone mineral densities while
old BMSCs transplantation may actually accelerate the decline of
bone density.
Micro-CT imaging of femurs from BMSCs transplanted animals.
To visualize the bone micro structure of the BMSCs transplanted
animals, distal tibiae were isolated and examined with a Siemens
Inveon CT/PET Multimodality system (Siemens Medical Solutions
Inc., Knoxville, TN, USA) operating in the cone-beam mode.
Imaging was obtained at 80 kV and 500 CT images were
reconstructed with a down sample factor of 1 using Cobra
Reconstruction software. As shown in Figure 6, there were clear
differences in the X-ray and micro-CT reconstruction images of
tibiae isolated from different groups of animals. Specifically, tibiae
from young animals showed thicker compact bone with denser
trabecular network (white/gray), small marrow space (black) and a
rod and plate aspect in the 3D microarchitecture (Figure 6A). As
expected, a more alveolar structure with a thinner trabecular bone
and less distinct plate structure was seen in the tibiae of old animals
(Figure 6B). Very interestingly, the transplantation of young BMSCs
substantially increased the trabecular network and bone density of
oldmice(Figure6C).Suchchangesofbonestructurewerenotfound
in the old mice transplanted with old BMSCs which retained typical
thinner trabecular bone and lesser plate feature (Figure 6D). The
differences of bone structure among various treatment groups were
also reflected in 3D analyses of tibia bone. Figure 6E shows that the
volume ratios of bone to total tissue of young mice and old mice
transplanted with young BMSCs were significantly greater than old
mice and old mice transplanted with old BMSCs. Similar differences
werealsoseeninthetrabecularseparation,corticalthickness,trabecular
thickness and trabecular number among the test groups (Figure 6E).
Figure 3 | Osteogenic activities and BMSCs migration in bone (n57 for each groups). (A) Prior to radiation, there were few AP1 (pink) cells in bone
fromoldmicewhilethereweresignificantnumbersofAP1cellsinyoungones.Immediatelyfollowingirradiationtreatment,fewAP1cellswerefoundin
both groups, bar5100mm. (B) Six months following BMSCs transplantation, the presence of transplanted BMSCs and osteogenic activities were
visualized based on anti-GFP (green) and osteocalcin immunohistochemistry staining (red). AP1 cells were also imaged inside or on the edge of bone,
bar5100mm. The density of (C) GFP1 BMSCs and (D) AP1 cells in the bones from mice with either old BMSCs or young BMSCs transplants was
determined. **:p ,0.01.
www.nature.com/scientificreports
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Aging is the best predictor of osteoporosis
1,3. Aging-associated
changes in metabolism and hormonal balance have been shown to
play important roles in the progression of osteoporosis
13,14. Indeed,
supplemental intake of calcium (1000–1200 mg) and vitamin D
(700–800 IU) is currently recommended to prevent and, perhaps,
treat osteoporosis
5,6. In addition, appropriate and persistent exercise
has been shown to increase bone density and reduce the risk of hip
fracture in older women
15. Pharmacologic interventions
2,5,6, includ-
ing anabolic agents such as hormone replacement, bisphosphonates,
calcitonin, raloxifene, teriparatide and alternative therapies are cur-
rently being used in osteoporosis prevention and treatment.
Although these strategies are at least partially effective, recent evid-
ence indicates that the loss of functional osteogenic progenitor cells
with age might beresponsible forage-related osteoporosis. Specially,
the proliferative capacity of osteogenic progenitor cells derived from
the bone marrow of old mice is substantially lower than those from
young ones
7. A significant age-dependent decline of cells with osteo-
genic potential has also been observed in human bone marrow
16,17.
Additionally, alkaline phosphatase-positive osteogenic progenitor
colonies(CFU-ALP)andtotalfibroblastic colonies(CFU-F)ofmice,
rats and human BMSCs have also shown declined osteogenic and
growth potential with age
18–20.
TodeterminewhetherthesenescenceofBMSCscontributestothe
accelerated bone mass loss, we compared the in vitro differentiation
capacity of BMSCs isolated from young (1–2 months old) vs. old
mice (20–24 months old). Our results indicate that the differenti-
ationcapability of young BMSCs is significantly higher than thoseof
oldBMSCs.Thisisinagreementwithrecentfindingsthatmesenchy-
mal stem cells derived from mice, Wistar rats, rhesus monkeys and
humans show declined viability and capacity for differentiation with
age.
10–12,17,19. The molecular mechanism(s) underlying BMSCs aging
are unclear. Cumulative DNA damage has been reported to affect cell
aging
21. Upon DNA damage (i.e., double strand breaks), phosphory-
lated H2AX accumulates at sites of DNA lesions, which triggers a
DNA damage checkpoint response
22. 53BP1 is a DNA damage check-
pointresponsemediatorandplaysanimportantroleinDNAdamage
checkpointresponseand damagerepair
23. Our results showthatthere
is a good agreement between BMSCs aging and 53BP1 and c-H2AX
up-regulation. However, we cannot conclude yet whether cumulative
DNA damage is the cause of BMSCs aging and loss of function.
Byanalyzingbonesectionsfromtransplantedmice,wehavefound
that more young BMSCs than old BMSCs appeared in the tissue
sections, suggesting that the migratory ability of BMSCs may decline
with age. This is supported by parallel observations that the migra-
tion of endothelial progenitor cells is significantly reduced in older
humans and mice
24,25. It has also been shown that the migratory
ability of human BMSCs significantly declines with age
26. Such
aged-related impaired migration has also been shown in human
lung, skin and dermal fibroblasts
27,28. The inability of BMSCs from
aged individuals to migrate throughout the body may impede the
distribution of the BMSCs and later regeneration of various tissues
and organs which might, in the present case, lead to osteoporosis.
It is well established that, compared with young individuals, old
animals have significant reductions of osteogenic activity in bone,
including the expression and production osteocalcin
29. Our results
showed that transplantation of BMSCs from young mice leads to a
dramatic increase of AP and osteocalcin activities in bone tissue. On
the other hand, the transplantation of BMSCs from old animals had
no such effect. These results suggest that young BMSCs can actively
migrate,anddifferentiateintoavarietyofcells,includingosteoblasts.
However, old BMSCs may somehow lose such capability. These
observationsareinagreementwithseveralrecentfindings.First,with
increasing age, murine bone marrow derived stem cells lose their
ability to adhere, proliferate, and undergo chondrogenic and osteo-
genic differentiation
10. Second, stem cells isolated from old animals
were found to engender less bone formation when subcutaneously
implanted in porous hydroxyapatite scaffolds than stem cells recov-
ered from young ones
30. Finally, a negative correlation has been
reported between in vitro osteogenic activity of CD1051 human
MSCs and cell donor age
31.
Using Micro-CT imaging it has been established that, during the
development of age-related osteoporosis, there are substantial
decreasesofbonetototaltissueratio,trabecularthickness,trabecular
number, and cortical thickness while the values for trabecular sepa-
ration are increased significantly
32,33. In fact, these bone physical
characteristics have been used as indicators for diagnosis and treat-
ment of osteoporosis
34,35. Trabecular architecture parameter assess-
ments using CT or MRI as a bone mineral density-independent
determinant of bone strength are able to separate patients with and
without osteoporotic fractures better than with BMD alone, and
parametersoftrabeculararchitecturearealsomoresensitivetotreat-
ment effects than BMD
36. Equally important, trabecular architecture
parameters and microstructure measurements using micro-CT have
proven to be a very good tool to evaluate osteogenic activity and new
bone formation
37,38. We find that, simply by transplantation of
BMSCsfromyounganimals,itispossibletorestorealmostallaspects
ofbonemicrostructureinagedanimals.However,transplantationof
BMSCs from old animals had little or no effect on bone microstruc-
ture in similar animals. Similar morphological changes have been
shown to reflect osteogenic activities
39.
Surprisingly, we observed that recipients of BMSCs from young
animals had significantly increased life spans. It is not clear how
administration of young BMSCs leads to increased longevity but it
Figure 4 | Effect of BMSCs transplantation on the life span of Balb/c
mice. (A) The lifespan of mice without (control, n510) and with BMSCs
transplants from either young (n514) or old mice (n510). (B) The mean
survival time of control animals vs. BMSCs transplanted mice. Kaplan-
Meier Log Rank pairwise comparison statistics revealed significant
differences of lifespan between the control and young BMSCs
transplantation groups (p50.009), and between young BMSC
transplantation and old BMSCs transplantation groups (p50.002). There
was no significant difference between the control and old BMSCs
transplantation groups (p50.846). **:p ,0.01.
www.nature.com/scientificreports
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regeneration and thereby slow down the aging process. This potential
influence isbased onthe following evidence. First, EGFPpositivecells
were found in many vital organs, including skin, heart, spleen, lung,
liver,bonemarrow,etc.Second,studieshaveshownthattransplantsof
youngmesenchymalstemcellswereabletorestorecardiacangiogenic
function and also improve functional outcomes in old mice after a
myocardial infarction
40. Third, similar transplants ofyoung mesench-
ymal stem cells in old female mice were also reported to postpone
age-related reproductive failure and improve offspring survival
41.I n
addition, bone marrow transplantation from young donors was also
foundtobeabletorejuvenatetheB-celllineageinagedmice
42.Fina lly,
myofiber-associated satellite cell transplantation has been found to be
effective in the prevention of age-related sarcopenia
43. Overall, these
observations support the idea that young BMSCs transplantation
might extend life span by improving the functions of multiple vital
organs, including lung, heart, and immune system, albeit through
presently unknown mechanisms.
In conclusion, the transplantation of BMSCs from young animals
effectively restores bone microstructure and density inaged animals.
As an unexpected consequence, old mice receiving BMSCs from
young animals also have longer life spans compared to control mice
or mice with transplanted BMSCs from old mice. These findings pro-
vide a potential link between stem cell activities and aging. However,
further studies are needed to determine mechanisms through which
BMSCs transplantation restores bone function and prolongs life.
Methods
Materials.Dulbecco’sModifiedEagle’sMedium(DMEM),FetalBovineSerum(FBS)
and Pen-Strep were purchased from Invitrogen Corporation (Carlsbad, California),
trypsin, ascorbic acid-2-phosphate, dexamethasone and b-glycerolphosphate were
purchased from Sigma-Aldrich (St. Louis, MO). BMP-2 was from R&D Systems
(Minneapolis, MN). Primary antibodies CD34, CD44, CD105, CD29, SCA-1, CD45,
osteocalcin, 53BP1, c-H2AX, were purchased from Santa Cruz Biotechnology Inc
(Santa Cruz, CA)and BDBioscience (SanJose, CA).FITCand Texas Redconjugated
secondary antibodies were from Jackson ImmunoResearch laboratories, Inc. (West
Grove, PA).
BMSCs Isolation, Proliferation, and Characterization. BMSC isolations were
carried out on EGFP transgenic male C57Bl/6 mice and Balb/c mice (Taconic Farm,
Hudson, NY) following standard bone marrow aspirate procedure
44. Young and old
BMSCs were recovered from 1–2 months old and 20–24 months mice, respectively.
CD105,CD29,CD44,CD34andCD45expressiononthe2ndpassageofBMSCsfrom
Figure 5 | BMDmeasurementsofBalb/cmice. (A)Thedistributionofbonedensityinuntreatedmicefrom1–33months(opencircleswithpolynomial
treadline, order52, n599). (B) The distribution of BMD in mice transplanted with BMSCs isolated from young mice (green solid triangles with green
dash linear trendline, n515) compared with untreated controls (gray open circles with linear trendline, n59). (C) The distribution of BMD in mice
transplantedwithBMSCsisolatedfromoldmice(orangeopentriangleswithorangedashlineartrendline,n510)comparedwithuntreatedcontrols(gray
open circles with linear trendline, n59). (D) Direct comparisons of BMD distribution between mice transplanted with young BMSCs (green solid
triangles with green dash linear trendline, n515) and those with old BMSCs (orange open triangles with orange dash linear trendline, n510). (E)
Comparison of the averages of BMD at different age ranges.
www.nature.com/scientificreports
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protocols. To determine their differentiation ability, the 2nd passage of BMSCs
underwent osteogenic, neurogenic, adipogenic, and myogenic differentiation by
culture the cells in respective induction medium
45–48. Immunohistological staining of
aging related markers 53BP1 and c-H2AX, were carried out to compare the
expression profiles between different sources of BMSCs.
BMSCs transplantation in vivo. For BMSCs transplantation study, we used female
Balb/C mice (female, 18–24 month old). All mice underwent whole body
X-irradiation(500 cGy)usingaVarianClinacLinearaccelerator(2100C)toeradicate
host bone marrow stem cells using established procedures
49. Twenty four hours
following the irradiation, mice were intravenously transplanted with EGFP-
transgenic BMSCs (1310
6 cells/ animal) from either young or old mice. More than
95%ofthehostmicesurvivedafterradiationandsubsequentBMSCstransplantation.
GFP and osteocalcin immunohistochemistry were applied to evaluate in vivo BMSCs
populationandosteogenicactivities.TheextentofBMSCmigrationwasestimatedby
measuring the densities of GFP positive cells in femur tissue sections. Bone alkaline
phosphatase activities were also determined to reflect the degree of osteogenic
activities based on the established procedure
50. The animal use protocols were
reviewed and approved by the Institutional Animal Care and Use Committee of the
University of Texas at Arlington.
Measurement of bone mineral density. All treated and control animals were
monitored every 2–3 weeks for their BMD using Lunar PIXImus machine (Lunar
PIXImus Co., Madison, WI). BMD of the femur joint was analyzed using Lunar
PIXImus 2.0 software.
Micro-CT imaging of femurs microarchitecture. At the end of the experiments,
tibia bone samples were examined with a Siemens Inveon CT/PET Multimodality
system (Siemens Medical Solutions Inc., Knoxville, TN, USA) operating in the cone-
beam method. Imaging was obtained at 80 kV and 500 mA with a focal spot of
58 mm. The total rotation of the gantry was 360u with 1080 rotation steps obtained at
an exposure time of approximately 715 ms/frame. The images were attained using a
binfactorof1andanaverageframeof3.Underhighmagnificationtheeffectivepixel
size was 11.34 mm. CT images were reconstructed with a down sample factor of 1
using Cobra Reconstruction software. Three-dimensional reconstruction of the bone
was analyzed with Inveon Research Workplace software. For each bone sample, the
trabecular region was defined as the epiphysis of the distal femur excluding the
growth plate. Regions of interest (ROI) were drawn approximately 180 mm from the
growth plate and extended approximately 200 pixels along the cortical wall. Fewer
contours needed to be drawn since a routine facility calculated all the intermediary
masks by interpolation. The ROI’s were interpolated yielding a final ROI
encompassing approximately 65 slices. The trabecular bone was separated from the
bonemarrowandanalyzedtodeterminethefollowingparametersusingtheprovided
algorithm software. For trabecular bone measurement, the volume of interest (VOI)
wascomprisedonlyofcancellousbone,andthecorticeswereexcluded.Thefollowing
parameters were determined: bone volume fraction (BV/TV) is the ratio of total
trabecular bone volume (BV) to total tissue volume (TV, including bone and
marrow). Trabecular thickness (Tb.Th.) is derived from the average thickness of the
Figure 6 | Micro structure of distal tibia bones from controls and young/old BMSCs transplanted mice 6 months after transplant. Left images are the
three-dimensional (3D) images of mouse tibias, middle images are the X-ray images taken from a KODAK in vivo FX machine, and the right images are
the 3D microCT reconstruction images of samples of mouse tibias. Typical bone images from (A) young control mouse, (B) old control mouse, (C)
mouse transplanted with young BMSCs, (D) mouse transplanted with old BMSCs, (E) Tabulated parameters and statistical analyses of bone
microstructure based on micro-CT analyses, n55 for each group.
www.nature.com/scientificreports
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average distance between trabecular structures within the VOI. Trabecular number
(Tb.N) was derived according to the number of trabecular structures intersected per
unitlength within the VOI. The cortical wallthickness(Cor.Th) wasmeasured in the
center of the boneshaft.Four measurements weretakenperpendicularto the cortical
wall on either side of the shaft and averaged together.
Statistical analyses. Statistic was analyzed using IBM SPSS Statistics 19. All
parameters were expressed as means 6 SD, except mean life span was express as
means 6 SE. Kaplan-Meier Log Rank pairwise test was used to compare life spans
between different groups. One-way ANOVA and Post Hoc Scheffe test was used for
multiple comparisons of BMD between groups at different age periods. Two tailed
independent samples t-test was used in other parameters comparison between
groups. p,0.05 was considered significant.
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